- Oral Presentation and Poster Show Ability of Lead Candidate,
Eravacycline, to Help Protect Against Community-Acquired, Complicated
Intra-Abdominal Infections -
- Poster Shows Usefulness of Preclinical Candidate, TP-271,
Against Community-Acquired Bacterial Pneumonia -
WATERTOWN, Mass.--(BUSINESS WIRE)--
Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that it has
presented results from studies that demonstrate efficacy of two
next-generation antibiotic candidates against community-acquired
multi-drug resistant (MDR) infections. These studies — which support the
efficacy of the company's lead candidate, eravacycline,
in the treatment of patients with community-acquired, complicated
intra-abdominal infections (cIAIs), as well as the potential of
pre-clinical candidate TP-271's activity against community-acquired
bacterial pneumonia (CABP) — were described in one oral presentation and
two poster presentations at the 23rd
European Congress of Clinical Microbiology and Infectious Disease
(ECCMID). The Congress occurs from April 27 to 30, 2013 in Berlin,
"These data continue to demonstrate the potential of our antibiotic
franchise, both in terms of our lead candidate eravacycline, and the
strength of our pre-clinical program, " said Guy
Macdonald, Tetraphase President and Chief Executive Officer.
"Antibiotic resistance, particularly among the difficult-to-treat
populations with Gram-negative infections, represents a potential global
health crisis. We are pleased by the results that our compounds display,
particularly in the crucial areas of multi-drug resistant,
The oral presentation, which focused on results from a global Phase 2
trial, examined eravacycline compared to standard-of-care ertapenem for
the treatment of community-acquired cIAIs. Results showed that
eravacycline demonstrated efficacy in all populations at all study time
points when examining both the microbiological activity of the pathogens
and the clinical cure rates. The findings strongly support the use of
eravacycline in the treatment of cIAI, including those hard-to-treat
patients with multi-drug resistant gram-negative infections.
Following are details for each of Tetraphase's three presentations:
"Characterization of baseline pathogens and microbiological eradiation
in a phase 2 trial for treatment of complicated intra-abdominal
infections comparing eravacycline (TP-434) to ertapenem." C. Fyfe, J.
Deane, T. Grossman, P. Horn, G. Moore, D. Sahm, J. Studeny, S.
Walpole, and J. Sutcliffe. Presented as an oral presentation (#277) on
Sunday, 28 April 2013 at 12:06 p.m. CEST as part of ECCMID's session
on "Clinical trials of antimicrobial agents"
"The fluorocycline TP-271 is potent against major complicated
community-acquired bacterial pneumonia (CABP) pathogens." T. H.
Grossman, C. Fyfe, W. O'Brien, D. E. Low, M. B. Minyard, K. Waites, J.
Dubois, J. A. Sutcliffe. Presented as a poster (# 1641) on Sunday
April 28, 2013 from 1:30 — 2:30 p.m. CEST as part of the session "New
antibacterial agents other than beta-lactams."
"Time to defervescence as an early marker of clinical response in
patients with complicated intra-abdominal infections treated with
eravacycline or ertapenem." P. Horn, J. Sutcliffe, S. Walpole.
Presented as a poster (# 2107) on Monday, April 29 from 1:30 — 2:30
p.m. CEST as part of the session "Endocarditis and other serious
infections— clinical observations."
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its
proprietary chemistry technology to create novel antibiotics for serious
and life-threatening multi-drug resistant infections. Tetraphase's lead
product candidate, eravacycline, is a fully synthetic tetracycline
derivative being developed as a broad-spectrum intravenous and oral
antibiotic for use as a first-line empiric monotherapy for the treatment
of multi-drug resistant infections, including multi-drug resistant
Senior Vice President & CFO
Sam Brown Inc.
Source: Tetraphase Pharmaceuticals, Inc.
News Provided by Acquire Media